“…The clinical and biological characteristics of our patients suggest that this complication Alive and free of disease (6) Died of rapid disease progression (4) Alive and free of disease (5) Alive but with ongoing disease progression (12) MCL, mantle cell lymphoma; AIHA, developing autoimmune haemolytic anemia; IFT, immunophenotype obtained by flow cytometry and/or immunohistochemistry, all cases being CD19+ and CD20+; BM, bone marrow; PB, peripheral blood; IGHV, immunoglobulin heavy chain variable region genes; NA, not assessed; DAT, direct antiglobulin test; NE, not evaluable because administered together with chemotherapy; R, rituximab; CVP, cyclophosphamide, vincristine, prednisone; PBSC, peripheral blood stem cell transplant; BAC, bendamustine, cytarabine; MOF, multiorgan failure; BR, bendamustine and rituximab; SOX11 was + when expressed by immunohistochemistry at the nuclear level. Ann Arbor stage A or B: the absence of constitutional (B-type) symptoms is denoted by adding an "A" to the stage.…”